AI to accelerate drug discovery and development timelines

Over 3,000 drugs have been developed or repurposed using AI.

Digital transformation, particularly through AI, is anticipated to streamline drug discovery and development processes, enhancing efficiency and accelerating innovation.

A GlobalData survey revealed that a majority (82%) of pharmaceutical professionals believe digital transformation could significantly or moderately shorten development timelines.

This facilitates faster identification of potential drug candidates and the optimisation of clinical trial processes, said Urte Jakimaviciute, Senior Director of Market Research and Strategic Intelligence at GlobalData.

Meanwhile, over 3,000 drugs have been developed or repurposed using AI, most of which are still in the discovery or preclinical stages.

“The fact that most AI-driven drugs are in early stages suggests that more companies are increasingly turning to AI to explore and expand their drug pipelines,” Jakimaviciute added.